Oncolytics Biotech (ONCY) news
Recent news
Oncolytics Biotech - New method of use patents expected to provide protection into late 2040s
Oncolytics Biotech has recently secured a series of new method of use patents, which are expected to extend its intellectual property protection into the late 2040s. These patents cover novel therapeutic applications of the company’s lead product candidate, extending the potential commercial…
AInvest Wire · 20h agoOncolytics Biotech - Three patent applications pending; one to be converted to track one this quarter
Oncolytics Biotech Inc. (TSX: ONCY) has disclosed that it currently has three patent applications pending, with one of these converted to track one status during the current quarter. The company recently announced that the United States Patent and Trademark Office has issued new patent protecting…
AInvest Wire · 20h agoOncolytics Biotech - Company expects to add new composition of matter patent for next generation Pelareorep
AInvest Wire · 20h agoOncolytics Biotech - New method of use patent for Pelareorep issued in several countries; U.S. issuance expected soon
AInvest Wire · 20h agoOncolytics Biotech - Expects interim part A clinical update by year-end 2026
AInvest Wire · Sep 28, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.